Esketamine vs Ketamine: Which Is Right for Treatment‑Resistant Depression?

Key Takeaways



• Ketamine and esketamine can act quickly for depression symptoms, but only intranasal esketamine, SPRAVATO®, is fda approved specifically for treatment-resistant depression.
• Esketamine is covered by most insurance plans, including Medicare and often Medicaid, when criteria are met; IV ketamine infusions are usually self-pay because ketamine treatment for depression is off-label.
• Ketamine is usually administered intravenously in infusion clinics; esketamine treatment is an in-clinic nasal spray program with REMS safety monitoring.
• Revitalizing Remedies in Hackettstown, NJ offers SPRAVATO treatment, TMS, psychiatry, therapy, diagnostic testing, and medication management for better mental health.
• Keep reading to compare esketamine vs ketamine on efficacy, safety, access, and treatment decisions.

Understanding Treatment‑Resistant Depression (TRD)

Treatment-resistant depression is commonly defined as inadequate response to at least two antidepressants taken at proper doses for about six weeks each.

TRD can involve:

• Persistent symptoms and worsening depression severity
• Loss of work, school, or family function
• Higher hospitalization risk
• Increased risk of suicidal ideation

Other antidepressants often target serotonin, norepinephrine, or dopamine. Ketamine and esketamine work through a different mechanism involving glutamate, the most abundant chemical messenger in the brain. At Revitalizing Remedies, we evaluate whether esketamine for treatment resistant depression, TMS, or other treatments may help patients who have not found relief.

What Is Ketamine?

Ketamine was developed as an anesthetic in the 1960s, and ketamine is approved by the fda as an anesthetic and pain management medication. At lower doses, research suggests it may treat depression rapidly.

In clinical psychiatry, ketamine is used off-label for depression, usually given intravenously or intramuscularly. Ketamine is most commonly administered as an intravenous infusion that usually lasts over 40 minutes, although it can also be given intramuscularly. There is no singular recommended administration schedule, but many clinics use 6–8 ketamine infusions over 2–4 weeks.

As of 2023, ketamine is not FDA-approved for the treatment of depression, which affects its availability and insurance coverage. Ketamine treatments for depression are not covered by insurance because it is not FDA-approved for this use, requiring patients to pay out of pocket.

What Is Esketamine (SPRAVATO®)?

Esketamine is the S-enantiomer of ketamine, formulated as esketamine nasal spray. Esketamine (Spravato) was approved by the FDA in 2019 specifically for the treatment of treatment-resistant depression and major depressive disorder with acute suicidal ideation or behavior.

Unlike ketamine, SPRAVATO is an fda approved medication for eligible patients. Esketamine therapy is delivered as intranasal esketamine under direct medical supervision in a clinical setting. Esketamine requires a 2-hour observation period in a certified clinic post-administration under the Risk Evaluation and Mitigation Strategy (REMS) program.

Esketamine treatment usually involves two sessions per week for the first four weeks, followed by weekly sessions, and then tapering to maintenance doses based on treatment response. Revitalizing Remedies provides SPRAVATO® in Hackettstown as part of ongoing care.

Chemical Structure and How They Work in the Brain

Esketamine and ketamine are chemically related medications that differ in their chemical structures, medical uses, approved delivery methods, and intensity of side effects, and understanding the science of Spravato and esketamine can help clarify how these differences affect treatment.

• Chemical structure: Ketamine is a racemic mixture composed of two stereoisomers: (R)-ketamine and (S)-ketamine (esketamine).
• Esketamine is the purified S-enantiomer of ketamine, which is thought to have a higher affinity for the NMDA receptor, enhancing its antidepressant effects.
• Both ketamine and esketamine work primarily through the glutamate system, which plays a key role in synaptic plasticity and mood regulation, differing from traditional antidepressants that target serotonin and norepinephrine.

By blocking NMDA receptors, short for n methyl d aspartate receptors, these treatments may help brain cells relay communication more flexibly. Glutamate is also an abundant chemical messenger involved in learning and mood. Lower doses of esketamine may provide relief with fewer side effects for some patients.

Similarities Between Ketamine and Esketamine

Ketamine and esketamine share core features:

• Rapid relief can occur within hours to days.
• Both may help many patients after multiple antidepressant failures.
• Both may reduce suicidal thoughts faster than standard medications.
• Both are Schedule III controlled substances.
• Both ketamine and esketamine must be administered under medical supervision in a clinical setting due to their potential side effects and the need for monitoring.

Both ketamine and esketamine can cause temporary side effects such as dissociation, dizziness, and elevated blood pressure, and both require patients to arrange safe transportation home after treatment.

Key Differences: Esketamine vs Ketamine

The biggest significant differences involve fda approval, administration, insurance coverage, and oversight.

Esketamine vs Ketamine for Treatment‑Resistant Depression

Both treatments can reduce depression scores meaningfully. IV ketamine often works faster than esketamine, with some patients experiencing relief after just one infusion. IV ketamine often brings significant mood relief faster than esketamine, sometimes after only 2 to 3 sessions.

Esketamine has been shown to provide rapid relief from depressive symptoms, often within hours, making it particularly beneficial for patients with treatment-resistant depression. Clinical trials indicate that esketamine can reduce depression symptoms in a majority of patients with treatment-resistant depression, with some studies reporting a 49.2% decrease in depression scores with IV ketamine compared to a 39.6% reduction with esketamine.

Esketamine has stronger FDA-reviewed long-term maintenance data, including relapse-prevention studies. Esketamine is the only drug besides lithium that has been proven to decrease suicidal thoughts, providing a significant advantage for individuals at high risk of suicide. See the FDA SPRAVATO safety information for more context.

Administration Experience: What Patients Can Expect

With IV ketamine therapy, patients arrive, receive an IV, complete an intravenous infusion over about 40 minutes, and remain monitored before going home. Practices vary, and some patients may also explore structured psychedelic-assisted therapy options under medical supervision when appropriate.

With esketamine nasal spray, patients complete vitals, medication review, supervised dosing, and monitoring for two hours. Esketamine is administered as a nasal spray, allowing for easier dosing and improved patient compliance compared to intravenous ketamine. No driving is allowed until the next day.

At Revitalizing Remedies, most patients receive step-by-step preparation before SPRAVATO treatment.

Side Effects and Safety Considerations

Both are generally well tolerated when monitored, but they are powerful medications. Common effects include dissociation, dizziness, blurred vision, nausea, hallucinations, sedation, and transient increases in blood pressure.

Both medications temporarily raise blood pressure and heart rate, peaking around 40 minutes post-dose. Common side effects of esketamine treatment include mild dissociation, sedation, and transient increases in blood pressure, which typically resolve within a few hours after administration. Both ketamine and esketamine can cause side effects such as dizziness, nausea, and hallucinations, but these effects are generally mild and subside shortly after treatment.

Extra caution is needed with uncontrolled hypertension, cardiovascular disease, pregnancy, substance use disorders, and some neurological conditions.

FDA Approval and Insurance Coverage

FDA approval matters because it affects standardization, safety review, and insurance plans. Esketamine’s fda approval allows it to be covered by most insurance plans, including Medicare, while ketamine treatments are typically not covered due to its off-label status.

Esketamine, on the other hand, is covered by most insurance plans, including Medicare, due to its FDA approval and established safety and efficacy. To qualify for insurance coverage for esketamine, patients typically need to have tried at least two other antidepressants without sufficient benefit or with intolerable side effects. Some plans also ask about oral antidepressants, although SPRAVATO’s TRD indication expanded in 2025 to include monotherapy for certain adults.

Revitalizing Remedies helps verify benefits, prior authorizations, and expected costs as part of its broader mental health treatment services in Hackettstown, NJ.

Costs, Accessibility, and Practical Trade‑Offs

Ketamine infusions may have a lower per-session cash price, but patients often pay fully out of pocket. Esketamine may have a higher listed price, but insurance can significantly reduce patient cost, especially when accessed through empowering mental health solutions in New Jersey.

Also consider:

• Transportation after every session
• Time in clinic, often 2–3 hours
• Maintenance frequency
• Facility and follow-up costs
• Whether TMS or medication management may be a better treatment option

Esketamine, Ketamine, and the Path to Better Mental Health

Neither treatment is a cure by itself. For sustained better mental health, ketamine and esketamine should be paired with therapy, medication review, lifestyle support, and careful follow-up.



Do not self-medicate with illegally obtained ketamine. Medically supervised care is essential, especially for complex mental health conditions.

How Revitalizing Remedies Approaches Esketamine vs Ketamine

Revitalizing Remedies is a specialty psychiatry and mental health clinic in Hackettstown, New Jersey. We do not operate as a ketamine infusion center; instead, we offer FDA-approved intranasal esketamine, TMS, psychiatry, therapy, diagnostic testing, and coordinated depression treatment.

Our process includes psychiatric assessment, medication history review, discussion of SPRAVATO and TMS, coordination with current providers, and progress monitoring over time. We accept major insurance plans, including Medicare and Medicaid.

Other Advanced Depression Treatments at Revitalizing Remedies

Not every patient is a candidate for ketamine treatment or esketamine. Our toolkit includes multiple evidence-based options, similar to other regional centers that focus on mental health and TMS care:

• TMS therapy, an approved by the fda noninvasive option for MDD
• Psychiatry and medication management
• Diagnostic testing and blood work for thyroid, vitamin, and medical contributors
• Micronutrient IV therapy when appropriate, along with resources such as our Revitalizing Remedies wellness insights blog
• Traditional psychotherapy

Johns Hopkins Medicine and other academic centers continue to highlight the importance of individualized care for TRD, a principle that guided the development of Revitalizing Remedies’ comprehensive services in Hackettstown.

Choosing Between Esketamine and Ketamine: Questions to Ask Your Provider

Ask:

• Do I meet criteria for treatment resistant depression?
• Is this treatment FDA approved for my condition?
• Who monitors me during and after sessions?
• What side effects should I expect?
• Will my insurance cover esketamine therapy?
• What are my total costs over months, not just one visit?

These questions help you make informed decisions.

Get Started with Esketamine Treatment at Revitalizing Remedies

If you recognize your experience in this article, Revitalizing Remedies can help. Schedule an initial consultation in Hackettstown, NJ to review your history, explore SPRAVATO® and TMS options, and understand coverage.

Our team can verify insurance coverage, including Medicare and Medicaid, and explain patient forms before your first visit. Reaching out is a strong first step toward treatment, support, and relief.

Frequently Asked Questions About Esketamine vs Ketamine